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Abstract: Tissue engineering is a multidisciplinary field focused on in vitro reconstruction 
of mammalian tissues. In order to allow a similar three-dimensional organization of in vitro 
cultured cells, biocompatible scaffolds are needed. This need has provided immense 
momentum for research on “smart scaffolds” for use in cell culture. One of the most 
promising materials for tissue engineering and regenerative medicine is a hyaluronan 
derivative: a benzyl ester of hyaluronan (HYAFF
®). HYAFF
® can be processed to obtain 
several types of devices such as tubes, membranes, non-woven fabrics, gauzes, and 
sponges. All these scaffolds are highly biocompatible. In the human body they do not elicit 
any adverse reactions and are resorbed by the host tissues. Human hepatocytes, dermal 
fibroblasts and keratinocytes, chondrocytes, Schwann cells, bone marrow derived 
mesenchymal stem cells and adipose tissue derived mesenchymal stem cells have been 
successfully cultured in these meshes. The same scaffolds, in tube meshes, has been 
applied for vascular tissue engineering that has emerged as a promising technology for the 
design of an ideal, responsive, living conduit with properties similar to that of native tissue.  
 
Keywords: HYAFF; hyaluronan; tissue engineering 
 
 
OPEN ACCESSInt. J. Mol. Sci. 2009, 10 
 
2973
1. Introduction  
 
The major goal of tissue engineering is to replace, repair or enhance the biological function of 
damaged tissue or organs. The principal obstacle to clinical transplantation today is the shortage of 
donor organs. For this reason, tissue engineering and regenerative medicine have become promising 
and important fields of research, which may offer new sources of tissues and organs for 
transplantation. Repair of skin, bone, liver and blood vessels is likely to become of clinical interest 
when three dimensional cell and tissue reconstructive procedures are correctly matched with the 
appropriate supporting biomimetic materials. 
Recent developments in the multidisciplinary field of tissue engineering have yielded many novel 
tissue replacements and implementation strategies. Scientific advances in biomaterials, stem cell 
isolation, growth and differentiation factors and biomimetic environments have created unique 
opportunities to fabricate tissues in the laboratory. One of the major challenges now facing tissue 
engineering is to optimize three dimensional (3D) functional recovery, a factor dependent on 3D 
structural complexity, as well as the biomechanical and functional stability of the laboratory-grown 
tissues destined for transplantation.  
In the complex scenario of biopolymers useful on Tissue Engineering field hyaluronic acid holds an 
important position. Hyaluronic acid (HA) is a naturally occurring non sulphatated glycosaminoglycan 
consisting of a linear sequence of D-glucuronic and N-acetyl-D-glucosamine. It is present in connective 
tissue, in the synovial fluid of articular joints and in the vitreous humor of the eye. HA is important in 
many biological processes such as tissue hydration, cell differentiation, cell behavior and tissue repair. 
In recent years a novel hyaluronan polymer based scaffold has shown surprising properties in the field 
of tissue engineering [1,2]. This semysinthetic insoluble polymer obtained by the hyaluronic acid 
esterification with benzyl alcohol (HYAFF
® Fidia Advanced Biololymers - F.A.B Abano Terme, Italy) 
is biocompatible, completely biodegradable, soluble in DMSO, exhibits good stability to hydrolysis, 
forms contact angle measurements and presents a strong ability to interact with polar molecules. [3-5] 
With the phase inversion technique, the esterification of all the carboxyl group with alcohols totally 
esterified hyaluronic acid derivatives (namely HYAFF11
®) could be available in the form of films, 
non-woven fabrics, gauzes, sponges, tubes and microspheres. All these devices have been used in 
several medical applications for tissue repair, controlled drug release, nerve regeneration and as wound 
dressings or in microparticles easily enriching with active proteins (i.e. growth factors) for drug 
delivery application [6,7].  
In the present review we report the most popular applications obtained with this biomaterial in 
tissue engineering, regenerative medicine and in clinical practice. 
 
2. Skin  
 
Successful treatment of burns and skin lesions requires the development of skin substitutes that can 
replace autografts. With the continued evolution of cell culture systems and the promising biological 
performance of three-dimensional support scaffolds, advancements have progressed rapidly in this 
field of tissue engineering. Initially, results obtained with autologous keratinocyte sheets, particularly 
in the treatment of burns, were encouraging. Kertinocytes obtained from a small patient biopsy are Int. J. Mol. Sci. 2009, 10 
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able to growth rapidly on a HYAFF11
® film, named Laserskin
®, developing a keratinocyte 
culture/transfer device. Indeed, keratinocytes cold be transferred on the healing bed using this 
hyaluronic acid film. Laserskin
® is a sheet of maximally esterified (and therefore minimally-soluble) 
benzyl ester of hyaluronan (HYAFF11 material) in which micro perforations, with diameters of 40 mm 
and 500 mm, are made with a laser-drill [8-13]. Initially it was designed as a transfer mechanism for 
keratinocytes from tissue culture to wound bed. In fact cells applied to its surface in vitro were allowed 
to proliferate across it and migrate down the perforations. It could then be applied with the colonized 
surface uppermost, allowing the proliferating cells to populate the wound bed via the pores [14]. 
However, these constructs were too delicate and difficult to handle in the clinical setting due to its 
thinness. Researchers have therefore turned their attention to developing composite skin substitutes in 
which keratinocytes are cultured on an engineered dermal layer whose aim is to create an easy-to-
handle and more resistant skin substitute. In keeping with the bilaminar concept, scaffolds created 
using modified hyaluronic acid have been employed for the co-culture of autologous fibroblasts and 
keratinocytes. In principle, the concept of in vitro organogenesis allowed the development of a two-
layered living skin equivalent that consists of both dermal and epidermal cells resembling full 
thickness skin with a fibroblast layer and a well-developed multilayer epithelium [13]. Shortly after 
grafting, skin organotypic cultured grafts normalize their tissue architecture, basement membrane 
structure and barrier function [14,15]. Development of skin equivalents has progressed further by the 
addition of endothelial cells to co-culture systems, aiming to create a microcapillary network inside the 
dermal layer. Tonello and colleagues have obtained promising results by co-culturing three different 
human cell types - fibroblasts, keratinocytes and endothelial cells - obtained from full-thickness skin 
biopsies, onto a non-woven hyaluronic acid based scaffold (HYAFF11
®) [15]. Initially, fibroblasts 
were seeded to allow for the production of the main extracellular matrix molecules necessary for 
proliferation and differentiation of keratinocytes and for endothelial cells proliferation and 
organization into capillary-like structures [15]. Extracellular matrix molecules secreted by fibroblasts 
(i.e. Collagen type I; collagen Type II; collagen type VI; fibronectin; laminin) provide the 
physiological environment for endothelial cell differentiation, keratinocytes have also been shown to 
play an important role by providing endothelial cells with the production of vascular endothelial 
growth factor (VEGF) [16]. Moreover, it is well known that in presence of hyaluronidase enzymes 
hyaluronic acid is catabolized by to either oligosaccharides or larger polymer and that these 
oligosaccharides stimulate cytokine secretion for endothelial cell proliferation; attachment and 
organization [17,18]. In turn, endothelial cells secrete an organized sub-endothelial matrix that is 
critical to the success of vascular grafts since the strength of the scaffold-matrix-cell interface 
determines the ability of the cells to resist blood flow. The presence of a microcapillary network 
should facilitate the take of a skin substitute, particularly for the treatment of full-thickness wounds. 
Furthermore, an endothelialized skin substitute should accelerate the revascularization process at the 
transplant site by inoculation of the capillary-like structures with the local wound vessels [15]. 
 
3. Cartilage  
 
Injuries to articular cartilage are known to have limited self-healing capacity and if left untreated 
have the tendency to develop into early degenerative joint changes. Conventional surgical treatments Int. J. Mol. Sci. 2009, 10 
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for joint lesions are not fully satisfactory because they often result in a repair tissue that is 
fibrocartilaginous and exhibits poor mechanical properties [19]. Autologous chondrocyte implantation 
(ACI) was first introduced in Sweden in 1987 as an innovative therapeutic option alternative to 
traditional surgical methods for cartilage repair, such as bone marrow stimulation techniques and 
mosaicplasty. A large amount of evidence currently is available in the literature concerning the clinical 
results obtained with ACI indicating that the treatment is associated with substantial pain reduction and 
improved joint functionality, resulting in improved health and economic outcomes. These findings, 
together with the documented evidence of hyaline like cartilage formation at the graft site, in many 
cases support the hypothesis of this cell-based treatment being regenerative, not only reparative. 
However, despite the promising clinical results obtained so far, the use of ACI is associated with a 
number of limitations essentially correlated with the complexity and morbidity of the surgical 
procedure and the frequent occurrence of periosteal hypertrophy. To overcome these limitations, tissue 
engineering has emerged as an innovative field of research with the potential to recreate three-
dimensional structures such as cartilage to be used as a replacement for damaged tissue and to 
regenerate a functional organ in vivo. Engineered cartilage, generated by chondrocytes expanded from 
a small tissue biopsy and cultured in a 3D environment (e.g., porous biodegradable scaffolds), has the 
potential to support the regeneration of large joint defects, allowing early postoperative rehabilitation 
and functionality. From a biologic point of view, the scaffold for cartilage engineering must promote 
chondrocytes attachment and in-vitro proliferation as well as favor the expression and maintenance of 
a cell differentiated phenotype. An appropriate polymer scaffold should allow for three-dimensional 
distribution of chondrocytes stimulating the synthesis of extracellular matrix molecules and preventing 
the loss of cell phenotype for a proper cartilage function once implanted [20]. Indeed, human articular 
chondrocytes derived from knee articular biopsies and cultured as a monolayer de-differentiate after a 
few days of cell expansion, but a three-dimensional environment promotes re-differentiation to the 
cartilage phenotype. RNA analysis and immunohistochemistry reveal that cells sustain the expression 
of cartilage genes and proteins, such as collagen type II, type IX, and type X, aggrecan and sox 9 
[21,22]. In this contex, Hyalograft
® C Autograft, a commercial three-dimensional HYAFF11 scaffolds 
enriched with autologous chondrocytes, has reveled in clinical medium-term results on the treatment of 
0.5 to 15 cm
2 defects more than 90% of patients expressing an improvement in knee symptoms and 
functionality and a very limited number of complications. The Hyalograft® C Autograft was simply 
placed into the prepared lesion, where it was stable and without the need for any fixation method.  
With regard to the direction of tissue regeneration overtime, histological observation of specimens 
demonstrated that, in most mixed tissue, regeneration occurred first in contact with the subchondral 
bone and then proceeded toward the outer region. Soon after grafting, chondrocytes are known to 
proliferate and to synthesize extracellular matrix cartilage with a poor molecular network rich in 
collagen type I leading to the formation of immature tissue that, in time, differentiate and become 
organized into hyaline tissue with cells in columns immersed in a specialized extracellular matrix rich 
in collagen type II. The Hyalograft C autograft is then defined as a tissue-engineered graft composed 
of autologous chondrocytes grown on a three-dimensional HYAFF11® scaffold. This innovative 
approach was first introduced into clinical practice in a number of European countries in 1999 for the 
treatment of full-thickness cartilage defects and has generated growing interest in the orthopaedic 
community with more than 4,800 patients treated so far. From several analyses of second-look and Int. J. Mol. Sci. 2009, 10 
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third-look cartilage biopsies from patients with cartilage lesions treated with Hyalograft® C Autograft, 
Brun et al. [23] stated that the plasticity of mature chondrocytes is sufficient to enable de-differentiated 
cells to revert to differentiation. For this reason, mature cells can be used in in vitro cartilage tissue 
reconstruction with impressive results in terms of grafting and clinical outcome [24,25]. 
More recent studies allowed favorably comparing this tissue-engineering based approach with the 
clinical outcome of ACI and so setting the superiority of cell-based treatments. The most relevant 
difference with the ACI technique remains the implantation method. The use of HYAFF11® matrix 
significantly facilitates the surgical procedure avoiding the use of a periosteal flap and allowing the use 
of minimally invasive techniques therefore reducing surgical time and morbidity. Overall, the results 
indicate that treatment with the Hyalograft C Autograft is associated with improvements in relief of 
symptoms, mobility, pain reduction and quality of repaired cartilage tissue in the majority of patients 
with a limited number of adverse events reported, hence representing a valid option for the treatment 
of cartilage lesions in the knee [26]. 
 
4. Adipose Tissue  
 
The correction of soft-tissue defects presents a challenge in plastic and reconstructive surgery. The 
implantation of isolated and culture-expanded adipose precursor cells is a solution to this problem 
because these cells differentiate into adipocytes when implanted in vivo. While several experimental 
approaches using adipose derived stem cells (ADSC) with various biomaterials for adipose tissue 
engineering have been proposed, many of these biomaterials are currently not commercially available. 
Consequently, the identification of suitable scaffolds that are readily available for adipose tissue 
engineering is necessary in order to apply these technologies to realistic therapeutic strategies [27]. 
Candidates of such scaffolds include type I collagen sponge, non-woven polyglycolic acid (PGA) and 
hyaluronic acid gel. Hyaluronic acid gel has been applied as wrinkle filler in the field of cosmetic 
medicine [28]. Hyaluronic acid is one of the natural extracellular matrix compuoi and is reported to be 
a suitable scaffold for adipose tissue engineering. It was used for this purpose as a sponge or a gel. The 
in vivo efficacy of constructs in generating mature adipose tissue has been clearly correlated to the in 
vitro cell inoculation of the scaffolds and to the structure and type of biopolymer used [29]. It was 
demonstrated that open hyaluronan sponges with interconnecting pores of 50 to 340 µm had deeper 
penetration of adipocytes than either collagen sponges or non-woven hyaluronan meshes [30]. Even 
larger scaffold pores were shown to allow better cell penetration, although maturation of the progenitor 
cells was compromised [31]. In contrast to rigid biopolymer carriers, biological hydrogels such as 
fibrin and Matrigel (Becton Dickinson, Heidelberg, Germany) lack of structural rigidity and deform 
easily [32]. Matrigel has been demonstrated to effectively support angiogenesis and preadipocyte 
maturation both in vitro and in vivo. However, its use is restricted to experimental purposes because its 
origin is from a murine sarcoma. Therefore, it would be highly desirable if alternative gels with 
adipogenic characteristics were available for human clinical use. It would be advantageous to have an 
implantable biomaterial that would both support the growth of adipocytes and actively induce 
neovascularization of the graft. It is well known that hyaluronic acid and its derivatives are actively 
angiogenic [33]. Injectable hyaluronic acid-based gels mixed with undifferentiated pig preadipocytes 
were evaluated in an autologous pig model to analyze their suitability as filler for soft tissue Int. J. Mol. Sci. 2009, 10 
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reconstruction [33]. Two types of gels with varying degrees of amidation were tested [33]. 
Microscopical examination of explanted tissue samples revealed the formation of highly vascularized 
adipose. The small size of the adipocytes supported the belief that these fat cells were newly formed, 
differentiated (pre)adipocytes [33]. The adipose tissue was found around mature vessels in addition to 
newly formed small vascular structures. In summary, these findings demonstrated that hyaluronic acid 
gel is applicable for generating adipose tissue in gels, displaying adipogenic as well as angiogenic 
properties, and strongly indicate its use as a matrix material for use as an injectable strategy for soft 
tissue reconstruction [34]. 
 
5. Gland Tissue Reconstruction 
 
Treatment of hepatic/pancreatic diseases has been greatly improved by the advent and evolution of 
liver/pancreas transplantation. Yet as demand for donor organs continues to increase beyond 
availability, the need for alternative therapies becomes evident. Several approaches, including 
extracorporeal devices, cell transplantation and tissue-engineered constructs, have been proposed as 
potential adjuncts or even replacements for transplantation. Tissue engineering of implantable cellular 
constructs is an emerging cellular therapy for hepatic disease. Hepatocytes and Langerhans islets 
known to be anchorage dependent, are immobilized on scaffolds, encapsulated in aggregates, or 
cultured ex vivo to form liver ‘‘organoids’’ that are then surgically transplanted [35]. In the first years 
of the XXIst century Catapano et al. reported a preliminary investigation on HYAFF11
® and hepatic 
cultures, [35] suggesting that polymers made of hyaluronan benzyl esters could be promising substrata 
for in vitro hepatocyte culture. Hepatocytes adherent to films of hyaluronan benzyl esters were as 
functional as cells adherent to collagen. Cells cultured in non-woven fabrics of the ethyl hyaluronan 
ester (HYAFF7
®) exhibited an initial capacity to eliminate ammonia comparable to that of cells 
adherent to collagen but synthesizing urea at a significantly greater rate. In the long term, cells cultured 
on HYAFF7
® non-woven fabrics also retained much more of their initial metabolic activity. This latter 
feature makes these substrata particularly interesting for hepatocyte culture in bioreactors, where long-
term maintenance of liver-specific function is an essential requirement for the success of the treatment. 
Following on these consideration Zavan et al. [36,37] investigated whether the extracellular matrix 
produced by fibroblasts cultured on HYAFF11
® non-woven fabric constructs could influence 
hepatocyte morphology and metabolism. In addition, they investigated hepatocyte transplantation in 
the rat subdermis using the extracellular matrix enriched scaffold (EMES) as a carrier. Results 
indicated that hepatocytes cultured within an environment-enriched device such as these EMES 
scaffolds maintain their typical morphology during the entire culture period. With regard to metabolic 
activity, such as albumin secretion, urea synthesis and ammonia elimination, in vitro  cultured 
hepatocytes exhibited a continuously decreasing metabolic capacity overtime. When cultures were 
implanted into the subdermal tissue of nude mice, hepatocytes were observed in the innermost regions 
of the scaffold, where they maintained their native hepatic cell morphology, pyramidal cell shape and 
large round nuclei, although their density tended to progressively decline, probably due to either 
apoptosis and/or an inability to self-renew. 
As regards to beta cells of pancreatic origin, their cultures on HYAFF11
® sponges not only ensured 
a constant vitaly (MTT value did not show any increase in time) but also the cells are able to maintain Int. J. Mol. Sci. 2009, 10 
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their original phenotype (i.e. ditizon positive labeling: a specific vital dye used for pancreatic islet 
staining) [36,37]. 
 
6. Peripheral Nerve Regeneration  
 
Peripheral nerve regeneration is a serious clinical problem. As early as 1880, experimental 
investigators and clinicians alike bridged the cut ends (stumps) of a peripheral nerve by inserting them 
in a tube (nerve chamber) fabricated from a large variety of materials. Still today, coaptation of the two 
nerve ends is commonly used to repair short nerve defects. When larger nerve gaps exist (20 mm or 
longer in humans), the current clinical gold standard for repairing larger nerve deficits involves using 
sensory nerve autografts. An analysis of clinical outcomes with autograft use suggests that a critical 
need for engineered alternatives exists. Autografts are plagued by issues such as a shortage of donor 
nerves, a mismatch of donor nerve size with the recipient site and occurrences of neuroma formation; 
even in the best-case scenarios complete recovery of function is rare. Driven by enormous clinical 
need, interest in peripheral nerve regeneration has become a prime focus of research and area of 
growth within the field of tissue engineering. Therefore, the need for synthetic alternatives to 
autografts is compelling and would be of great surgical benefit if they could match or exceed autograft 
performance. Experimental configurations that have maximized facilitation of peripheral nerve 
regeneration are those in which the tube wall comprised degradable polymers, including collagen and 
certain synthetic biodegradable polymers, and was cell-permeable rather than protein-permeable. Tube 
fillings that showed very high regenerative activity were suspensions of Schwann cells, a solution 
either of acidic or basic fibroblast growth factor, insoluble Extracellular matrix (ECM) substrates 
rather than solutions or gels, polyamide filaments oriented along the tube axis and highly porous, 
insoluble analogs of the ECM with specific structure and controlled degradation rate. These materials 
are attractive because their chemical and physical properties can be modified by physical coating, 
plasma treating and chemical bonding through adhesion mediators [38-40]. The majority of artificial 
polymers that have been studied belong to the polyester family, which includes polyglycolides and 
polylactides. Some disadvantages of these polymers in tissue engineering applications are their poor 
biocompatibility, release of acidic degradation products, poor processability and loss of mechanical 
properties very early during degradation. HYAFF11
® is known for its biodegradability and 
biocompatibility, as well as its capacity to promote adhesion and proliferation of different cell types. In 
light of these consideration Zavan et al. [41] tested the ability of this biomaterial to allow in vitro 
adhesion and proliferation of Schwann and endothelial cells obtained from the same peripheral nerve 
sample assuming that endothelial and peripheral nervous cells positively interact together to stimulate 
coordinated peripheral nerve and correlated microcapillary regeneration. The possibility of creating a 
microvascularized peripheral nerve substitute is very intriguing and opens up a completely new 
scenario for in vivo nerve regeneration. 
Results confirmed that tube devices made of HYAFF11
® based scaffolds are a good substrate for 
both in vitro peripheral nerve cell culture and nerve explants. Cells derived from rat sciatic nerve can 
be plated on these scaffolds where they attach, proliferate and colonize all the device surfaces. The cell 
population obtained from nerve digestion is represented by Schwann cells, endothelial cells and 
fibroblast-like cells that can be co-cultivated to obtain a microvascularized nerve substitute. Int. J. Mol. Sci. 2009, 10 
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This finding supports the evidence reported in recent literature of coordinated regeneration of the 
peripheral nerve and corresponding microcapillary network. Schwann cells secrete vasculogenic 
growth factor to stimulate contemporary microcapillary regeneration. The presence of a microcapillary 
network in vitro should improve the outcome of in vivo implantation, favoring prompt reconstitution of 
the vascular channels and the arrival of oxygen and nutrients to the cells inside the scaffold.  
 
7. MSC Differentiation 
 
Mesenchymal stem cells (MSCs) are pluripotent self-renewing cells capable of generating all major 
skeletal tissues, such as cartilage, bone, fat, tendon, muscle, when grown in appropriate in vivo/in vitro 
environments. MSCs have been successfully isolated from the bone marrow or from adipose tissue of 
various species including human, rat, mouse and rabbit. Aguiari et al. [42] reported the ability of 
adipose derived Mesenchymal stem cells to in vitro commit in adipose tissue, cartilage and bone on 
HYAFF11
® based scaffolds, whether Zavan et al. [43] reported that human and rat bone marrow 
derived MSC show the same behavior in terms of cell proliferation, differentiation and morphological 
organization in 3D scaffolds in presence of both cartilage or bone external stimulus. In light of their 
multilineage differentiating potential and their capacity to undergo extensive replication without losing 
this capacity, MSCs have an enormous potential in the fields of cell therapy and tissue engineering. 
Radice et al. [44] applied MSC for the repair of osteocohondral defect in rabbit knee. The starting idea 
of this experimental model was that MSC could be applied as valid alternative approach to 
differentiated chondrocytes for cartilage repair. It has been hypothesized that in adult life tissues, such 
as cartilage, cannot repair because of the lack of a sufficient quantity of mesenchymal precursors able 
to divide and restore the original tissue architecture and function. In order to investigate further the 
potential application of these three-dimensional scaffolds in tissue engineering, this study was 
conducted with the aim of using non-woven scaffolds for the in vitro proliferation of human and rabbit 
bone-marrow-derived mesenchymal progenitors. Then, an experimental model of osteochondral 
lesions in the rabbit knee was used to ascertain the tolerability and safety of these HYAFF11
® 
scaffolds used with or without progenitor cells. In light of the encouraging results obtained, the authors 
concluded that HYAFF11
® non woven meshes are suitable support for tissue engineering, with 
mesenchymal progenitor cells actively dividing and giving rise to a loose extracellular matrix inside 
the interfibrillar space of the biomaterial. These pluripotent cells express collagen type IIA, a typical 
marker of a prechondrogenic state. When this “cellularized construct” was implanted into a rabbit knee 
cartilage defect, with or without cells, no inflammatory reaction was noted and the scaffolds were 
almost completely resorbed four months after implantation. Furthermore, in the end of the treatment, 
inside the HYAFF11
® material bone marrow progenitor cells were able to differentiate to 
chondrocytes which, in turn, at the level of the superficial cartilage layer, integrated with the pre-
existing cartilage margins, retaining their morphology. Inside the subchondral bone, the typical 
modifications of endochondral ossification occurred, such as hypertrophy, calcification, and 
substitution by cancellous bone. 
The same results were obtained by Grigolo et al . [45], who used MSC for the treatment of 
osteoarthritis (OA). With the aim to explore a new approach to treat OA patients suffering from early 
degenerative lesions of hyaline cartilage, they transplanted in an experimental animal model of OA a Int. J. Mol. Sci. 2009, 10 
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hyaluronan-based scaffold (Hyaff11
®) seeded with Mesenchymal Stem Cells obtained from bone 
marrow and expanded in culture. Results obtained confirm, with statistically significant differences, 
the higher quality of the regenerated tissue obtained with scaffolds carrying mesenchymal stem cells 
compared to the scaffold alone. As a results, the authors concluded, it is possible to demonstrate that 
HYAFF11
®, a hyaluronan-based scaffold, provides promise for mesenchymal stem cell implantation 
and that may have application for the treatment of early OA in humans. 
The behavior of MSC embedded in biomaterials, in the long term and in the context of pathological 
joint, is under extensive characterization. As regards the in vitro chondrogenic differentiation of MSCs 
it requires a complex interaction of growth factors and cell-cell, cell-matrix interactions and the three-
dimensional support to maintain their differentiated phenotype in vitro. Different factors, like bone 
morphogenetic proteins (BMPs), insulin growth factor-1 (IGF-1) and transforming growth factor-β 
(TGFβ) promote chondrogenic effects in vitro or in vivo. [46]. In vitro and in vivo data indicate that the 
differentiation of isolated chondrocytes onto this scaffold allows the progressive increase for known 
constituents of cartilage matrix and the repair of damaged cartilage. The repair of human cartilage is 
mainly performed by clinicians using mature chondrocytes grown onto a scaffold. MSCs are a good 
alternative to chondrocytes for cartilage regeneration. To obtain new information on the sequence of 
cellular and molecular events during chondrogenesis, Lisignoli et al.  [47] analysed human MSC 
chondrogenic differentiation in vitro onto a hyaluronic acid biodegradable three-dimensional scaffold, 
in a defined medium in the presence of two different concentrations of TGFβ1 as chondrogenic growth 
factor. Cellular proliferation and the expression of chondrogenic genes were analyzed by real-time 
PCR and immunohistochemical techniques while cell morphological evaluation was performed by 
light and electron microscopy. With this study the authors demonstrate that chondrogenic 
differentiation of human MSCs onto a hyaluronic acid based scaffold is dependent on the 
concentration of TGFβ used. Moreover, they confirm that, since the scaffold is made of hyaluronic 
acid, as a cellular cross-linker, it may represent a first step in bringing the cells into close contact so 
favoring interactions with other ECM molecules. 
 
8. HYAFF
® for in Vivo Vessel Regeneration 
 
With the evolution of tissue engineering, the choice of materials for vascular scaffolding has shifted 
from purely synthetic biomaterials to biological polymers, such as extracellular matrix (ECM) proteins 
(i.e. collagen, fibrin), that could hypothetically more faithfully elicit native cell responses and likewise 
regenerate damaged tissue [48].  
However, the necessity to chemically stabilize such biopolymers and process them to remove 
immunogenic donor epitopes can compromise their native biological/mechanical characteristics [48]. 
Thus, recent studies have focused on ECM-based biomaterials, such as proteoglycans and 
glycosaminoglycans (GAGs), which could be useful as scaffolds for vascular endothelial cell (EC) 
regeneration, due to their presence in the vascular intima and media and frequent amenability to 
chemical stabilizion with little biological alteration [48]. One such GAG is hyaluronan (HA), whose 
content and form in vessels varies Hyaluronic acid cues for functional endothelialization of vascular 
constructs state of development and health [48,49].  Int. J. Mol. Sci. 2009, 10 
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Artery-Bioregeneration Assist Tube (ABAT) were tested in different animal models. ABAT 
(HYAFF11
® tubules, 2 mm diameter, 1 cm length) were grafted in the abdominal aorta of 30 rats as 
temporary absorbable guides to promote regeneration of vascular structures [50]. These experiments 
resulted in three novel findings: 1) complete endothelialization of the tube's luminal surface occurred; 
2) sequential regeneration of vascular components led to complete vascular wall regeneration 15 days 
after surgery; and 3) the biomaterial used created the ideal environment for the delicate regeneration 
process during the critical initial phases, yet its biodegradability allowed for complete degradation of 
the construct four months after implantation, at which time, a new artery remained to connect the 
artery stumps. This study assessed the feasibility to create a completely biodegradable vascular 
regeneration guide in vivo, able to sequentially orchestrate vascular regeneration events needed for 
very small artery reconstruction.  
The ability of ABAT grafts to develop into neovessels of larger size (4 mm) was tested in a porcine 
model, focusing on extracellular matrix (ECM) remodeling and elastin biosynthesis [51]. ABAT tubes 
(diameter 4 mm, length 5 cm) were implanted in an end-to-end fashion in the common carotid artery. 
All the animals survived the observation period without complications. Intimal hyperplasia (initiating 
at the anastomotic site) and graft thrombosis led to 3 cases of partial or complete occlusion, as 
demonstrated by histological examination. There were no signs of stenoses or aneurysms in the 
remaining grafts. After five months, the biomaterial was almost completely degraded and replaced by a 
neoartery segment composed of mature smooth muscle cells, collagen and elastin fibers organized in 
layers furthermore, it was completely covered on the luminal surface by endothelial cells. Whereas in 
previous small animal studies, patency rates were not optimal, those obtained in the present study 
using hyaluronan-based grafts of larger size confirmed the ability of these constructs to guide the 
development of a well-functioning neoartery, with the remarkable additional attribute of facilitating 
the formation of organized layers of elastin fibers. 
 
9. Conclusions 
 
Hyaluronan is a ubiquitous molecule present in all the connective tissues and it has been shown to 
exert a fundamental role in many biological processes such as water balance, cell recognition, 
embryonic development and wound healing both in adult and fetal life stages. When considering all 
these biological properties, for many researchers it has been tempting to think that hyaluronan 
derivatives may constitute suitable supports for the growth of mammalian cells. 
Recently, hyaluronan, a non-sulfated glycosaminoglycan, has been modified by the esterification of 
the carboxyl groups along the backbone with aromatic alcohols to form a water insoluble biomaterial 
which can be processed to produce spun fibers, woven and non-woven textiles, meshes, membranes, 
etc. In this review we showed that the benzyl ester of hyaluronan (HYAFF11
® materials) is a very 
suitable material both for tissue engineering or regenerative medicine. Indeed two commercial 
cellularized products find large clinical applications for skin and for cartilage regeneration. In this 
latter years, in which large attention is put on stem cells word, the ability of HYAFF11® to influence 
stem cell behavior open new intrigue applications. 
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